Synchrotron diffraction reveals distinct collagen-associated distributions of EGFR-targeted antibody and affibody in pancreatic tumors
Preprint
Abstract
Tumor extracellular matrix may influence the distribution of targeted agents differently across molecular formats. We compared how an antibody and an affibody targeting the same receptor distribute relative to collagen-associated tissue structure in pancreatic tumors. Methods: Cetuximab-IRDye700DX, an epidermal growth factor receptor (EGFR)-targeted fluorescent antibody, and ABY-029, an EGFR-targeted fluorescent affibody, were co-administered intravenously to 12 athymic nude mice bearing orthotopic pancreatic tumors: eight AsPC-1 and four PANC-1. Tumors were harvested at 3 or 24 h after injection, with four AsPC-1 and two PANC-1 mice at each time. Fluorescence images from 21 tissue slices were registered to scanning synchrotron X-ray diffraction (XRD) maps to compare each agent’s distribution with local collagen-associated diffraction intensity. Results: Cetuximab–XRD correlations were negative in all 12 mice at every evaluated binning scale (100–400 µm; all adjusted P = 0.0039). Cohort-average correlations were more negative for cetuximab than ABY-029 at all four scales (paired adjusted P = 0.0137–0.0381). At 400 µm, mean correlations were −0.502 and −0.249, respectively. ABY-029 correlations did not differ significantly from zero after adjustment. Vehicle controls showed positive background fluorescence–XRD associations. Conclusions: Cetuximab exhibited consistent inverse spatial associations with collagen-associated diffraction and stronger cohort-average associations than ABY-029. These findings show that agents targeting the same receptor can differ in their relationships with local tissue structure and support spatially resolved assessment of tissue access when selecting molecular formats for imaging and therapy.This publication has 26 references indexed in Scilit:
- Single-cell spatial pharmacobiology identifies conserved stromal barriers to therapeutic antibody delivery in human solid tumorsNature Biotechnology, 2026
- A first-in-class pan-lysyl oxidase inhibitor impairs stromal remodeling and enhances gemcitabine response and survival in pancreatic cancerNature Cancer, 2023
- Therapeutic Remodeling of the Tumor Microenvironment Enhances Nanoparticle DeliveryAdvanced Science, 2019
- Collagen Complexity Spatially Defines Microregions of Total Tissue Pressure in Pancreatic CancerScientific Reports, 2017
- Molecular Simulation of Receptor Occupancy and Tumor Penetration of an Antibody and Smaller Scaffolds: Application to Molecular ImagingMolecular Imaging and Biology, 2017
- Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human UseMolecular Imaging and Biology, 2016
- Enzymatic Targeting of the Stroma Ablates Physical Barriers to Treatment of Pancreatic Ductal AdenocarcinomaCancer Cell, 2012
- Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearanceAdvanced Drug Delivery Reviews, 2008
- Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generationNature Medicine, 2003
- Uptake of IgG in osteosarcoma correlates inversely with interstitial fluid pressure, but not with interstitial constituentsBritish Journal of Cancer, 2001